Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Gnt Pharma Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals sector. This active case is handled by 1 distinct examiner, BROOKS, CLINTON A, who currently manages 1 pending matter as the busiest examiner for the company. The portfolio's activity is limited to 1 distinct art unit. This narrow distribution indicates that the company's current interactions with the patent office are centralized under a single administrative path.
For a practitioner, having only one active matter assigned to one distinct examiner within a single art unit creates a highly focused prosecution environment. This concentration means that the success of the current portfolio depends entirely on the relationship with BROOKS, CLINTON A. While this simplifies the management of the portfolio, it also means there is no diversification of examiner perspectives. Strategic efforts should be directed toward understanding the specific examination history of this single examiner to optimize the chances of allowance for the 1 pending office action. This centralized path requires a deep dive into the art unit's specific policies to ensure the application meets all technical requirements.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BROOKS, CLINTON A | 1 | 67.8% | +19.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256350 | 2-HYDROXY-5-[2-(4-(TRIFLUOROMETHYLPHENYL)ETHYLAMINO)]BENZOIC ACID CRYSTAL FORMS AND PREPARATION METHOD THEREFOR | BROOKS, CLINTON A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256350 | 2-HYDROXY-5-[2-(4-(TRIFLUOROMETHYLPHENYL)ETHYLAMINO)]BENZOIC ACID CRYSTAL FORMS AND PREPARATION METHOD THEREFOR | BROOKS, CLINTON A | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18256350 | 2-HYDROXY-5-[2-(4-(TRIFLUOROMETHYLPHENYL)ETHYLAMINO)]BENZOIC ACID CRYSTAL FORMS AND PREPARATION METHOD THEREFOR | BROOKS, CLINTON A | 1621 | §102§112 | Non-Final OA | — | Pending | Jun 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial